Literature DB >> 10348283

Comparison between observation policy and fractionated stereotactic radiotherapy (SRT) as an initial management for vestibular schwannoma.

H Shirato1, T Sakamoto, Y Sawamura, K Kagei, T Isu, T Kato, S Fukuda, K Suzuki, S Soma, Y Inuyama, K Miyasaka.   

Abstract

PURPOSE: To compare the use of an observation policy with that of stereotactic radiotherapy (SRT) for treatment of vestibular schwannoma. METHODS AND MATERIALS: The study group consisted of 27 patients who underwent observation as an initial treatment (observation group) and 50 who received SRT (SRT group). The mean follow-up period was 35 months and 31 months, respectively. Stereotactic radiotherapy consisted of small-field fractionated radiotherapy (36-44 Gy in 20-22 fractions over 6 weeks) with or without a subsequent 4-Gy single irradiation boost.
RESULTS: Actuarial tumor control rate of the SRT group was significantly better than that of the observation group (p < 0.0001). The mean growth was 3.87 mm/year in the observation group and -0.75 mm/year in the SRT group (p < 0.0001). Eleven patients (41 %) in the observation group and 1 (2 %) in the SRT group received salvage therapy (p < 0.001). There was no difference in the actuarial Gardner and Robertson's class preservation curves for 5 years after the initial presentation.
CONCLUSION: Stereotactic radiotherapy using a fractionated schedule provides a better tumor control rate and a similar rate of deterioration for hearing levels compared to an observation policy. Initial SRT may be a reasonable alternative to a wait-and-see policy.

Entities:  

Mesh:

Year:  1999        PMID: 10348283     DOI: 10.1016/s0360-3016(99)00079-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Using Bayesian tissue classification to improve the accuracy of vestibular schwannoma volume and growth measurement.

Authors:  Elizabeth A Vokurka; Amit Herwadkar; Neil A Thacker; Richard T Ramsden; Alan Jackson
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

2.  CyberKnife for Treatment of Vestibular Schwannoma: A Meta-analysis.

Authors:  Hossein Mahboubi; Ronald Sahyouni; Omid Moshtaghi; Kent Tadokoro; Yaser Ghavami; Kasra Ziai; Harrison W Lin; Hamid R Djalilian
Journal:  Otolaryngol Head Neck Surg       Date:  2017-04-25       Impact factor: 3.497

3.  Focal radiation therapy of brain metastases after complete surgical resection.

Authors:  Gautam Bahl; Greg White; John Alksne; Lakshmi Vemuri; Matthew A Spear
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

4.  Hypofractionated stereotactic radiotherapy for acoustic neuromas: safety and effectiveness over 8 years of experience.

Authors:  Katsuyuki Sakanaka; Takashi Mizowaki; Yoshiki Arakawa; Norio Araki; Natsuo Oya; Jun A Takahashi; Nobuhiro Mikuni; Susumu Miyamoto; Nobuo Hashimoto; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2010-09-10       Impact factor: 3.402

5.  Fractionated Stereotactic Radiotherapy for Facial Nerve Schwannomas.

Authors:  Wenyin Shi; Varsha Jain; Hyun Kim; Colin Champ; Gaurav Jain; Christopher Farrell; David W Andrews; Kevin Judy; Haisong Liu; Gregory Artz; Maria Werner-Wasik; James J Evans
Journal:  J Neurol Surg B Skull Base       Date:  2015-09-14

6.  Three-dimensional conformal fractionated radiotherapy for spinal schwannoma with a paravertebral or an intraosseous component.

Authors:  Rikiya Onimaru; Kazutoshi Hida; Naoki Takeda; Shunsuke Onodera; Yukiko Nishikawa; Takashi Mori; Hiroki Shirato
Journal:  Jpn J Radiol       Date:  2015-10-27       Impact factor: 2.374

7.  Adherence to Long-Term Follow-up in Patients With Sporadic Vestibular Schwannomas Managed With Serial Observation.

Authors:  Mallory Raymond; Arian Ghanouni; Kaitlyn Brooks; Sarah M Clark; Douglas E Mattox
Journal:  OTO Open       Date:  2021-08-09

8.  Outcome after Radiotherapy for Vestibular Schwannomas (VS)-Differences in Tumor Control, Symptoms and Quality of Life after Radiotherapy with Photon versus Proton Therapy.

Authors:  Maike Küchler; Rami A El Shafie; Sebastian Adeberg; Klaus Herfarth; Laila König; Kristin Lang; Juliane Hörner-Rieber; Peter Karl Plinkert; Wolfgang Wick; Felix Sahm; Simon David Sprengel; Jürgen Debus; Denise Bernhardt
Journal:  Cancers (Basel)       Date:  2022-04-10       Impact factor: 6.575

9.  Safety and efficacy of fractionated stereotactic radiotherapy for acoustic neuromas.

Authors:  Shearwood McClelland; Bruce J Gerbi; Patrick D Higgins; James B Orner; Walter A Hall
Journal:  J Neurooncol       Date:  2007-07-11       Impact factor: 4.506

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.